[Vitamin K in the neonate: Recommendations update]

Area of Science:

• Neonatal Medicine
• Pediatric Hematology
• Pharmacology

Background:

• Hemorrhagic disease of the newborn (HDN) is rare but severe, causing bleeding in organs like the brain and liver.
• Current prevention relies on vitamin K1 (phytonadione) at birth, but evidence for optimal dosing strategies is limited.
• Existing recommendations often stem from expert opinion or retrospective data, with some debate on potential side effects.

Purpose of the Study:

• To analyze recent literature on vitamin K1 prophylaxis for HDN.
• To propose evidence-based, optimized dosing regimens for vitamin K1 administration in newborns.
• To provide clear guidelines for both term and premature infants, including alternative administration routes.

Main Methods:

• Systematic review and analysis of current scientific literature on vitamin K1 for HDN prevention.
• Development of proposed dosing schedules based on infant gestational age and birth weight.
• Consideration of oral, intravenous, and intramuscular administration routes and their respective dosages.

Main Results:

• A proposed oral regimen of three 2mg doses of vitamin K1 for term infants: at birth, discharge, and 1 month.
• For premature infants >1500g: weekly 2mg doses until term equivalent age.
• For premature infants <1500g: weekly 1mg until 1500g, then weekly 2mg until term equivalent age.

Conclusions:

• The proposed oral vitamin K1 dosing schedule aims to optimize HDN prevention in term and premature infants.
• Specific recommendations are provided for different weight categories of premature infants.
• Alternative parenteral routes (IV/IM) are suggested with a 50% dose reduction if oral administration is not feasible.